Status:
COMPLETED
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008...
Eligibility Criteria
Inclusion
- Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug
- Patient did not withdraw from the base protocol
- Patient agrees to practice effective birth control during the study
Exclusion
- Patient is receiving other standard and/or investigational anticancer therapy
- Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00907738
Start Date
August 1 2005
End Date
June 1 2010
Last Update
May 21 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.